Newborns and young infants with severe bacterial infections can be effectively treated outside hospital with simplified antibiotic regimens, reducing deaths and improving adherence. The Lancet study found that treatment failures were low in all three trials, and the risk of death was similar to infants who received hospital care.
A phase 1 clinical trial found the VSV-EBOV Ebola vaccine to be safe and elicit a robust immune response, with 93% of volunteers developing anti-Ebola antibodies within two weeks. The vaccine's higher dose showed a stronger antibody response.
The American Cancer Society's new report highlights disparities in cancer prevention and early detection efforts, including underutilized screening for colorectal and cervical cancers. Meanwhile, tobacco use remains a major cause of preventable disease and premature death, with wide variation by education and race/ethnicity.
Research found oxygen-depleted conditions and hydrogen sulfide poisoning in the Panthalassic Ocean during the end-Triassic mass extinction. The study provides direct evidence of anoxic and euxinic conditions affecting food chains, highlighting the potential consequences of rising CO2 levels on marine ecosystems.
Researchers have identified a new class of dopamine receptor antagonists that selectively target mosquito cells, offering a safer alternative to current insecticides. These chemicals are structurally distinct and target different biochemical paths in mosquitoes, reducing the risk of human exposure.
A new study found that Massachusetts health reform did not decrease preventable hospitalizations or close the racial gap in such rates, contrary to expectations. Access to outpatient care remained limited due to high copays and financial barriers.
A study of 14,348 Swiss individuals found that those with depressive symptoms have a higher risk of developing physical diseases, especially arthrosis and arthritis. The researchers suggest that lack of interest in physical activity or inflammatory processes may be key factors in this association.
Research in The FASEB Journal suggests that fenofibrate may become a viable treatment option for relieving pain, stimulating appetite, reducing nausea, and preventing depression. The study found that fenofibrate activates cannabinoid receptors, which could lead to the development of new drugs targeting these receptors.